Moore Capital Management LP Increases Stock Position in Sanofi $SNY

Moore Capital Management LP lifted its holdings in shares of Sanofi (NASDAQ:SNY) by 458.1% during the 4th quarter, Holdings Channel reports. The firm owned 275,060 shares of the company’s stock after buying an additional 225,779 shares during the period. Moore Capital Management LP’s holdings in Sanofi were worth $13,329,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. CSM Advisors LLC acquired a new stake in shares of Sanofi during the third quarter worth about $18,244,000. Natixis Advisors LLC lifted its position in shares of Sanofi by 11.8% during the third quarter. Natixis Advisors LLC now owns 3,113,381 shares of the company’s stock worth $146,952,000 after purchasing an additional 327,569 shares in the last quarter. XY Capital Ltd acquired a new stake in shares of Sanofi during the third quarter worth about $1,603,000. Regal Partners Ltd lifted its position in shares of Sanofi by 7.1% during the third quarter. Regal Partners Ltd now owns 1,657,539 shares of the company’s stock worth $78,236,000 after purchasing an additional 109,335 shares in the last quarter. Finally, NewEdge Wealth LLC lifted its position in shares of Sanofi by 63.1% during the third quarter. NewEdge Wealth LLC now owns 67,303 shares of the company’s stock worth $3,298,000 after purchasing an additional 26,035 shares in the last quarter. Institutional investors and hedge funds own 14.03% of the company’s stock.

Sanofi Stock Down 3.5%

Shares of NASDAQ:SNY opened at $42.50 on Thursday. The firm’s 50 day moving average price is $44.88 and its 200 day moving average price is $46.39. The stock has a market cap of $103.04 billion, a price-to-earnings ratio of 11.87, a price-to-earnings-growth ratio of 1.09 and a beta of 0.34. Sanofi has a fifty-two week low of $42.28 and a fifty-two week high of $52.68. The company has a quick ratio of 0.22, a current ratio of 1.01 and a debt-to-equity ratio of 0.17.

Sanofi Increases Dividend

The company also recently announced an annual dividend, which was paid on Wednesday, June 3rd. Investors of record on Monday, May 4th were issued a $2.4225 dividend. This represents a yield of 559.0%. This is a positive change from Sanofi’s previous annual dividend of $2.04. The ex-dividend date of this dividend was Monday, May 4th. Sanofi’s dividend payout ratio is 49.16%.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on SNY. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research report on Thursday, March 19th. Wall Street Zen cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 21st. Argus raised shares of Sanofi to a “strong-buy” rating in a research report on Monday, April 27th. BNP Paribas Exane cut shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price target on the stock. in a research report on Monday, April 20th. Finally, Weiss Ratings raised shares of Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, May 13th. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat.com, Sanofi currently has a consensus rating of “Hold” and an average target price of $51.00.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.